Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C
Sponsor: Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
This PHASE4 trial investigates HIV Infection and Hepatitis C, Chronic and is currently completed. Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status PHASE4
-
Apr 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE4
-
Mar 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
- Oxford University Clinical Research Unit, Vietnam
- University of Hawaii
- Viet Tiep Hospital
For direct contact, visit the study record on ClinicalTrials.gov .